Takeda must face US Amitiza antitrust case, judge rules
( October 29, 2025, 22:31 GMT | Official Statement) -- MLex Summary: Takeda Pharmaceuticals was denied a summary judgment against US antitrust claims over Amitiza. District Judge Myoung J. Joun found that plaintiffs sufficiently alleged that absent Takeda’s patent settlement with Par Pharmaceutical, a generic competitor would have entered the market. Joun said that while may bring flimsy circumstantial evidence, a reasonable jury may still find that there is an implicit no-authorized generic agreement, which could not have resulted from the independent actions of either Par or Takeda.See attached file. ...
Prepare for tomorrow’s regulatory change, today
MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.
Know what others in the room don’t, with features including:
- Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
- Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
- Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
- Curated case files bringing together news, analysis and source documents in a single timeline
Experience MLex today with a 14-day free trial.